6R-BH4 sapropterin dihydrochloride: Phase IIa data

In a 16-week, dose-escalation, open-label, U.S. Phase IIa study in 32 patients with SCD, 6R-BH4 showed a dose-dependant improvement in endothelial dysfunction with the mean PAT score for all patients ...